Meta-Analysis:
Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: a systematic review and meta-analysis
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1381 views | HTML 2650 views | ?
Abstract
Cheng Chen1,*, Zhen Chen1,*, Kun Wang1, Linkun Hu2, Renfang Xu1 and Xiaozhou He1
1Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, P.R. China
2Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, P.R. China
*These authors contributed equally to this work
Correspondence to:
Renfang Xu, email: [email protected]
Xiaozhou He, email: [email protected]
Keywords: prostatic neoplasms, prostatectomy, radiotherapy, quality of life
Received: August 21, 2017 Accepted: September 22, 2017 Published: October 05, 2017
ABSTRACT
The objective of this study is to compare health-related quality of life (QOL) outcomes between radical prostatectomy (RP) and external beam radiation therapy (EBRT) for localized prostate cancer. PubMed, EMBASE, the Cochrane Library and Web of Science (to July 2017) were searched. Pooled analysis of each domain-specific score was calculated in relevant studies, and its change with follow-up time was explored by sub-group analysis. A total of six studies containing 4423 patients were included. Men underwent RP was associated with worse urinary and sexual domain score than EBRT (standardized mean difference (SMD) = –0.59, –0.58; 95% confidence interval (CI) = –0.73 to –0.45, –0.72 to –0.44). In contrast, EBRT group had lower bowel domain score than RP group (SMD = 0.42, 95% CI = 0.33 to 0.52). The sub-group analysis revealed the most severe urinary and sexual QOL in RP as well as bowel QOL in EBRT group all happened in the first month post operation. The different performance of two treatments in three QOL domains diminished afterwards. Health-related QOL should be considered comprehensively when planning follow-up for men after RP or EBRT for localized prostate cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21519